Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
Robert J Fontana, Sabela Lens, Stuart McPherson, Magdy Elkhashab, Victor Ankoma-Sey, Mark Bondin, Ana Gabriela Pires Dos Santos, Zhenyi Xue, Roger Trinh, Ariel Porcalla, Stefan Zeuzem, Robert J Fontana, Sabela Lens, Stuart McPherson, Magdy Elkhashab, Victor Ankoma-Sey, Mark Bondin, Ana Gabriela Pires Dos Santos, Zhenyi Xue, Roger Trinh, Ariel Porcalla, Stefan Zeuzem
Abstract
Introduction: The presence or absence of cirrhosis in patients with chronic hepatitis C virus (HCV) infection influences the type and duration of antiviral therapy. Non-invasive markers, like serum aspartate aminotransferase (AST) to platelet ratio index (APRI), may help identify appropriate HCV treatment-naive patients for 8-week treatment with the pangenotypic regimen of glecaprevir/pibrentasvir.
Methods: This single-arm, open-label, international, prospective study (NCT03212521) evaluated the efficacy and safety of 8-week glecaprevir/pibrentasvir regimen in HCV treatment-naïve adults with chronic HCV genotypes 1-6 infection, APRI ≤ 1, and no prior evidence of cirrhosis. The primary and secondary outcomes were sustained virologic response at 12 weeks post-treatment (SVR12) by modified intent-to-treat (mITT) and intent-to-treat (ITT) analyses, respectively. Additional endpoints included virologic failures, treatment adherence, and genotype-specific SVR12 rates.
Results: Among the 230 patients enrolled, most were less than 65 years old (90%); 37% and 43% had a history of injection drug use or psychiatric disorders, respectively. SVR12 rates were 100% (222/222; 95% CI 98.3-100%) and 96.5% (222/230; 95% CI 94.2-98.9%) by mITT and ITT analyses, respectively. There were no virologic failures. ITT SVR12 rates were greater than 94% for all HCV genotypes. In patients with available data, treatment adherence was 99% (202/204). There were no grade 3 or higher laboratory abnormalities in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, and low rates of serious adverse events (2%).
Conclusions: Glecaprevir/pibrentasvir was highly efficacious and well tolerated in HCV treatment-naïve patients with APRI ≤ 1 and no prior evidence of cirrhosis.
Trial registration: ClinicalTrials.gov number, NCT03212521.
Funding: AbbVie. Plain language summary available for this article.
Keywords: Chronic hepatitis C; Direct acting antiviral; Glecaprevir/pibrentasvir; Infectious diseases; Simplification.
Figures
References
- World Health Organization . Global hepatitis report. Geneva: World Health Organization; 2017.
- Huppe D, Serfert Y, Buggisch P, et al. Hepatitis C therapy in Germany: results from the german hepatitis C registry 4 years after approval of the new direct antiviral substances (DAAs) Wiesbaden: Viszeralmedizin; 2018.
- Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32(3):344–355. doi: 10.1111/j.1365-2036.2010.04370.x.
- Xu F, Moorman AC, Tong X, et al. All-Cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin Infect Dis. 2016;62(3):289–297. doi: 10.1093/cid/civ860.
- Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–648. doi: 10.7326/M16-2575.
- Messori A, Badiani B, Trippoli S. Achieving sustained virological response in hepatitis c reduces the long-term risk of hepatocellular carcinoma: an updated meta-analysis employing relative and absolute outcome measures. Clin Drug Investig. 2015;35(12):843–850. doi: 10.1007/s40261-015-0338-y.
- Liu Z, Wei X, Chen T, Huang C, Liu H, Wang Y. Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: a systematic review with meta-analysis. J Gastroenterol Hepatol. 2017;32(3):548–557. doi: 10.1111/jgh.13500.
- Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C—the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41(6):497–520. doi: 10.1111/apt.13090.
- Cipriano LE, Goldhaber-Fiebert JD. Population health and cost-effectiveness implications of a “treat all” recommendation for HCV: a review of the model-based evidence. MDM Policy Pract. 2018;3(1):2381468318776634.
- Calvaruso V, Petta S, Craxi A. Is global elimination of HCV realistic? Liver Int. 2018;38(Suppl 1):40–46. doi: 10.1111/liv.13668.
- EASL European Association for the Study of the Liver recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511. doi: 10.1016/j.jhep.2018.03.026.
- AASLD. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2018. . Accessed 27 Nov 2018.
- World Health Organization . Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. Geneva: World Health Organization; 2018.
- Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018). 2018. . Accessed 22 Oct 2018.
- Shah H, Bilodeau M, Burak KW, et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190(22):E677–E687. doi: 10.1503/cmaj.170453.
- Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med. 2013;158(11):807–820. doi: 10.7326/0003-4819-158-11-201306040-00005.
- Asselah T, Lens S, Zadeikis N, et al. Analysis of AST to platelet ratio index (APRI) for determining eligibility for 8 weeks of glecaprevir/pibrentasvir. J Viral Hepat. 2018;25(S2):19–20.
- Rockstroh JK, Lacombe K, Trinh R, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study. Clin Infect Dis. 2018;67(7):1010–1017. doi: 10.1093/cid/ciy220.
- Gane Edward, Poordad Fred, Zadeikis Neddie, Valdes Joaquin, Lin Chih-Wei, Liu Wei, Asatryan Armen, Wang Stanley, Stedman Catherine, Greenbloom Susan, Nguyen Tuan, Elkhashab Magdy, Wörns Marcus-Alexander, Tran Albert, Mulkay Jean-Pierre, Setze Carolyn, Yu Yao, Pilot-Matias Tami, Porcalla Ariel, Mensa Federico J. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease. Clinical Infectious Diseases. 2019;69(10):1657–1664. doi: 10.1093/cid/ciz022.
- Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: an integrated analysis of HCV genotype 1–6 patients without cirrhosis. J Hepatol. 2018;69(2):293–300. doi: 10.1016/j.jhep.2018.03.007.
- MAVYRET (glecaprevir and pibrentasvir) [package insert]. North Chicago: Approved on August 2017. .
- D’Ambrosio R, Pasulo L, Puoti M, et al. Real-life effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 201970(3):379–87.
- Wiegand J, Naumann U, Stoehr A, et al. Glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis c virus infection: updated real-world data from the german hepatitis C-registry. Hepatology. 2018;68(S1):364A.
- MAVIRET (SmPC); AbbVie 2019/MAVYRET (US package insert); AbbVie 2019.
- Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nat Rev Gastroenterol Hepatol. 2017;14(11):641–651. doi: 10.1038/nrgastro.2017.106.
- Back D, Belperio P, Bondin M, et al. Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders. J Hepatol. 2018;68(S1):S280–S281. doi: 10.1016/S0168-8278(18)30778-5.
- Brown AS, Welzel TM, Conway B, et al. Adherence to pangenotypic glecaprevir/pibrentasvir treatment and SVR12 in HCV-infected patients: an integrated analysis of the phase 2/3 clinical trial program. J Hepatol. 2017;66(S1):114A–115A.
- Foster GR, Grebely J, Sherman KE, et al. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 and recent drug use. Hepatology. 2017;66(S1):636A–637A.
- Kamil RJ, Jerschow E, Loftus PA, et al. Case-control study evaluating competing risk factors for angioedema in a high-risk population. Laryngoscope. 2016;126(8):1823–1830. doi: 10.1002/lary.25821.
- Feld JJ, Sanchez Gonzalez Y, Pires dos Santos AG, Ethgen O. Clinical benefits, economic savings and faster time to HCV elimination with a simplified 8-week treatment and monitoring program in chronic F0-F3 naive patients in the US. Hepatology. 2018;68(S1):408A–409A.
- Brown RS, Jr, Hezode C, Wang S, et al. Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotypes 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study. Hepatology. 2018;68(S1):425A–426A.
Source: PubMed